Skip to content

US · GRFS · DRUG MANUFACTURERS - GENERAL

Grifols, S.A. (GRFS) intrinsic value and stock valuation

$8.15as of 2026-11-21 · Mkt cap 6.71B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Grifols, S.A. DCF and intrinsic value

InvestorsCraft values GRFS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from GRFS’s statements →

Grifols, S.A. Graham Number

Graham Number: $11.94d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Barcelona, CT 08174 grifols.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$7.23B+6.2% 5y CAGRd
20112025
Net income
$386.1M-9% 5y CAGRd
20112025
Free cash flow
$751.1M-2% 5y CAGRd
20112025
Total equity
$7.6B+2.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$7.23B$7.21B$6.59B$6.06B$4.93B
Operating income$1.19B$1.19B$782.3M$782.4M$595.1M
Net income$386.1M$156.9M$42.3M$185M$188.7M
EPSd$567.4K$230.8K$62.3K$272.2K$276.9K
Operating cash flow$1.01B$902.2M$218.7M-$-10.87M$597M
Capital expenditure-$-254.54M-$-371.37M-$-310.32M-$-375.56M-$-247.37M
Free cash flow$751.1M$530.8M-$-91.63M-$-386.43M$349.6M
Total assets$19.7B$21.4B$21B$21.2B$19.2B
Total debt$8.74B$10.1B$11B$9.75B$10.2B
Net debt$7.92B$9.11B$10.5B$9.2B$9.51B
Total equity$7.6B$8.61B$7.51B$7.98B$7.32B
Cash and short-term investments$824.7M$1B$646M$580.2M$2.69B
Income statement
20252024202320222021
Revenue$7.23B$7.21B$6.59B$6.06B$4.93B
Cost of revenue$4.65B$4.42B$4.11B$3.85B$2.97B
Gross profit$2.58B$2.79B$2.48B$2.21B$1.96B
Research and development expenses$358.3M$384M$395.3M$361.1M$354.9M
Selling, general and administrative expenses$1.02B$1.14B$1.27B$1.11B$1.06B
Other expenses$13.5M$74.5M$40.4M-$-37.66M-$-48.86M
Operating expenses$1.39B$1.6B$1.7B$1.43B$1.37B
Cost and expenses$6.04B$6.02B$5.81B$5.28B$4.34B
Interest income$32.7M$48.1M$62.4M$33.9M$11.6M
Interest expense$600.3M$773.2M$516.1M$444.5M$233.8M
Depreciation and amortization$432.2M$437.9M$446.4M$411M$359.8M
Ebitda$1.62B$1.48B$1.17B$1.19B$944M
Operating income$1.19B$1.19B$782.3M$782.4M$595.1M
Total other income/expenses, net-$-596.49M-$-748.02M-$-575.3M-$-444.42M-$-244.61M
Income before tax$590.7M$444M$207M$338M$350.5M
Income tax expense$110.5M$231.2M$43.4M$90.1M$85.1M
Net income$386.1M$156.9M$42.3M$185M$188.7M
Weighted average shares outstanding$680.6M$680M$679.8M$679.8M$681.6M
Weighted average diluted shares outstanding$680.6M$680M$679.8M$679.8M$681.6M
Balance sheet
20252024202320222021
Cash and short-term investments$824.7M$1B$646M$580.2M$2.69B
Net receivables$844.6M$1.08B$692.9M$774.2M$434.1M
Inventory$3.29B$3.56B$3.48B$3.24B$2.26B
Total current assets$5.07B$5.73B$6.13B$4.69B$5.51B
Property, plant and equipment, net$4.05B$4.31B$4.19B$4.28B$3.34B
Goodwill and intangible assets$9.56B$10.3B$8.01B$9.96B$7.23B
Long-term investments$592.8M$529M$451.9M$1.99B$2.27B
Total non-current assets$14.7B$15.7B$14.9B$16.5B$13.7B
Total assets$19.7B$21.4B$21B$21.2B$19.2B
Accounts payable$840.6M$852.3M$823M$788M$629M
Short-term debt$385.8M$639.7M$1.02B$681.3M$2.4B
Deferred revenue$77M$70.9M$0.00$37.8M$0.00
Total current liabilities$2.02B$2.16B$2.33B$2.02B$3.47B
Long-term debt$8.35B$9.45B$9.99B$9.07B$7.77B
Deferred revenue, non-current$0.00$13.9M$0.00$15.1M$0.00
Total non-current liabilities$10.1B$10.6B$11.2B$11.2B$8.44B
Capital lease obligations$968.6M$1.14B$1.11B$1.02B$873.7M
Total liabilities$12.1B$12.8B$13.5B$13.3B$11.9B
Common stock$120M$119.6M$119.6M$119.6M$119.6M
Retained earnings$0.00$156.9M$79.4M$0.00$248M
Accumulated other comprehensive income (loss)$4.37B$4.83B$4.41B$4.78B$4.41B
Total equity$7.6B$8.61B$7.51B$7.98B$7.32B
Total investments$592.8M$550.2M$568.4M$2.03B$4.29B
Total debt$8.74B$10.1B$11B$9.75B$10.2B
Net debt$7.92B$9.11B$10.5B$9.2B$9.51B
Cash flow statement
20252024202320222021
Net income$386.1M$444M$207M$361.3M$188.7M
Depreciation and amortization$432.2M$437.9M$446.4M$407.9M$359.8M
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-24.01M$22.4M-$-362.84M-$-609.22M-$-181.35M
Accounts receivable-$-30.74M-$-41.88M-$-68.81M-$-80.17M-$-16.81M
Inventory-$-93.17M$25.8M-$-411.44M-$-600.25M-$-157.47M
Accounts payable$90.3M$0.00$0.00$80.2M$0.00
Net cash provided by operating activities$1.01B$902.2M$218.7M-$-10.87M$597M
Investments in property, plant and equipment-$-406.31M-$-232.54M-$-224.44M-$-375.56M-$-247.37M
Acquisitions, net-$-99.9M-$-285.87M-$-29.47M-$-1.44B-$-519.13M
Net cash used for investing activities-$-556.15M$886.7M-$-394.72M-$-1.98B-$-854.15M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-123.91M$0.00$0.00-$-3.46M-$-125.7M
Dividends paid-$-122.95M-$-960K$0.00-$-590K-$-252.44M
Net cash used for financing activities-$-508.12M-$-1.36B$171.5M-$-173.49M$2.3B
Net change in cash-$-38.85M$450.2M-$-19.63M-$-2.13B$2.1B
Cash at end of period$824.7M$979.8M$529.6M$548M$2.68B
Operating cash flow$1.01B$902.2M$218.7M-$-10.87M$597M
Capital expenditure-$-254.54M-$-371.37M-$-310.32M-$-375.56M-$-247.37M
Free cash flow$751.1M$530.8M-$-91.63M-$-386.43M$349.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Grifols, S.A.

        Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

        CEO
        Jose Ignacio Abia Buenache
        Employees
        25.26K
        Beta
        1.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Grifols, S.A. (GRFS)?

        Grifols, S.A. (GRFS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GRFS undervalued?

        GRFS trades at a price of $8.15 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.